{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:47:50Z","timestamp":1740134870973,"version":"3.37.3"},"reference-count":10,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4,14]]},"DOI":"10.1182\/blood.2021015120","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T15:32:27Z","timestamp":1649950347000},"page":"2263-2264","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Chemotherapy-free regimens in frontline follicular lymphoma"],"prefix":"10.1182","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9036-9463","authenticated-orcid":false,"given":"Connie Lee","family":"Batlevi","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"15","key":"2022041415322089100_B1","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1182\/blood.2021013526","article-title":"Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study","volume":"139","author":"Bachy","year":"2022","journal-title":"Blood."},{"issue":"7","key":"2022041415322089100_B2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J."},{"issue":"10","key":"2022041415322089100_B3","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med."},{"issue":"1","key":"2022041415322089100_B4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"MAbs."},{"issue":"26","key":"2022041415322089100_B5","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1056\/NEJMc1714337","article-title":"Obinutuzumab treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med."},{"issue":"6168","key":"2022041415322089100_B6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science."},{"issue":"21","key":"2022041415322089100_B7","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","article-title":"Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay","year":"2009","journal-title":"Blood."},{"key":"2022041415322089100_B8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1182\/blood-2019-129422","article-title":"Results of a phase II study of obinutuzumab in combination with lenalidomide in previously untreated, high tumor burden follicular lymphoma (FL)","volume":"134","author":"Nastoupil","year":"2019","journal-title":"Blood."},{"key":"2022041415322089100_B9","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-148218","article-title":"Six-year results from the phase 3 randomized study relevance show similar outcomes for previously untreated follicular lymphoma patients receiving lenalidomide plus rituximab (R 2) versus rituximab chemotherapy followed by rituximab maintenance [abstract]","volume":"138","author":"Morschhauser","year":"2021","journal-title":"Blood."},{"author":"National Cancer Care Network NCCN Guidelines","key":"2022041415322089100_B10"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/15\/2263\/1891086\/bloodbld2021015120c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/15\/2263\/1891086\/bloodbld2021015120c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T15:32:34Z","timestamp":1649950354000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/15\/2263\/484612\/Chemotherapy-free-regimens-in-frontline-follicular"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":10,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2022,4,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021015120","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2022,4,14]]}}}